Aggregator

Cochrane Neuromuscular seeks Assistant Managing Editor/Information Specialist role - London, UK

3 years 3 months ago

Assistant Managing Editor/Information Specialist, fixed term to 31 March 2023
Deadline to apply: 7 March 2022
London, UK

Cochrane Neuromuscular is seeking an Information Specialist/Assistant Managing Editor on a fixed-term basis to 31 March 2023. This is an opportunity to contribute to evidence synthesis for the benefit of people affected by neuromuscular diseases.

Cochrane Neuromuscular is part of Cochrane, an independent, global organisation dedicated to synthesising research evidence to improve health. The group publishes reviews of evidence in neuromuscular disease in The Cochrane Database of Systematic Reviews (CDSR). Cochrane Neuromuscular is hosted by University College London NHS Hospitals Trust.

As postholder, you will have two primary areas of responsibility: literature searching, and assisting the Managing Editor in the management of submitted reviews. You will develop search strategies, run searches, and ensure correct documentation. Editorial tasks will include providing information to authors, checking manuscripts, overseeing peer review, tracking progress, and liaising between authors, editors, and reviewers. The appointee will also provide the review group with administrative support and may have the opportunity to assist review authors with systematic review tasks.

For details see nhsjobs.com. Closing date 7 March 2022.

Monday, February 28, 2022 Category: Jobs
Lydia Parsonson

抗血小板药物是否对慢性肾脏病患者有益?

3 years 3 months ago
抗血小板药物是否对慢性肾脏病患者有益? 研究问题是什么? 慢性肾脏病(chronic kidney disease, CKD)患者患心脏病的风险会增加,这将阻碍心脏或大脑的供血从而导致心脏病发作或中风。在一般的成年人群中,防止血栓形成的药物(抗血小板药物)可以预防因动脉栓塞而导致的死亡。然而,CKD患者使用抗血小板药物的益处可能会减少,因为对他们而言,与心力衰竭或猝死相比,动脉血栓并非是常见的死亡或住院原因。由于凝血机制的改变,CKD患者的出血倾向也有增加的趋势。因此,当患者患有CKD时,使用抗血小板药物可能会更危险。 我们做了什么? 本更新综述评估了在慢性肾脏病患者中,使用抗血小板药物预防心血管疾病和死亡的益处和危害以及其对透析血管通路(瘘管或移植物)功能的影响。我们发现了90项比较了抗血小板药物与安慰剂或无治疗的研究,以及29项直接比较两种抗血小板药物的研究。 我们发现了什么? 抗血小板药物可能预防心脏病发作,但不能明显降低死亡或中风的发生。使用这类药物治疗可能会增加大出血和小出血的风险。使用抗血小板药物还可以预防透析通路发生凝血。 结论 抗血小板药物对CKD患者的益处可能仅限于预防心脏病发作。这种治疗似乎不能预防中风或死亡,并且可能会导致严重出血,甚至需要住院或输血治疗。 作者结论:  对于接受透析治疗的CKD患者,抗血小板药物可能会降低心肌梗死和增加大出血的发生...

成人局灶节段性肾小球硬化的免疫抑制治疗

3 years 3 months ago
成人局灶节段性肾小球硬化的免疫抑制治疗 研究问题是什么? 肾病综合征是指肾脏无法将蛋白质保留在血液中而使其漏入尿液的一种状况。 局灶节段性肾小球硬化(focal segmental glomerulosclerosis, FSGS)是由肾活检所定义的一种肾病综合征的罕见病理,但在所确诊的病例中约有一半病人会发展为肾衰竭。FSGS可以分为三类:原发性(被认为是血液循环中的某种因素造成肾损伤)、遗传性(由于一个或多个基因的突变)和继发性(继发于其他原因所致,例如感染)。治疗的目的是完全或部分缓解尿蛋白,以延缓肾衰竭的发生。 我们做了哪些工作? 我们着眼于所有比较了泼尼松或其他免疫抑制剂(如环孢霉素和霉酚酸酯)和其他使用或不使用类固醇治疗的随机对照试验。 我们发现了什么? 我们发现了15项研究,共纳入553名受试者。其中5项研究将环孢素与其他不同的治疗相比较。联合4项研究(231名受试者)分析表明,相对于其他治疗方法,环孢素对肾病综合征的完全缓解更有效。然而,这些研究规模太小以及随访时间不够长,故无法确定环孢素是否可以降低肾衰竭的发生风险。 有9项小型研究比较了抑制人体免疫系统的不同药物。这些治疗方法均无法降低尿蛋白水平。 结论 由于纳入研究的样本量太少,没有足够的证据表明环孢素可能会降低FSGS患者的尿蛋白水平。我们需要新的药物来治疗伴有肾病综合征的局灶节段性肾小球硬化症,以预防肾衰...

管理婴儿呼吸急促(新生儿短暂呼吸急促)的治疗

3 years 3 months ago
管理婴儿呼吸急促(新生儿短暂呼吸急促)的治疗 系统综述问题 对呼吸异常急促(称为新生儿短暂呼吸急促)的婴儿进行药物和其他治疗是否可改善肺功能并减少对呼吸支持(即机械通气)的需要和/或症状持续时间? 研究背景 新生儿短暂性呼吸急促以快速呼吸(呼吸>60次/分钟)和呼吸窘迫(呼吸困难)为特征。其典型发生在刚出生两个小时内或怀孕34周后的婴儿。虽然新生儿短暂性呼吸急促通常无需治疗即可改善,但它有可能与儿童晚期的喘息有关。本Cochrane综述总览报告并批判性地分析了有关新生儿短暂性呼吸急促的不同管理治疗的益处与伤害的可及证据。 研究特征 我们纳入了6个Cochrane综述。其中4个将药物(沙丁胺醇、肾上腺素、皮质类固醇和利尿剂)与安慰剂进行了比较,而其余2个综述则评估了在没有向肺插管的情况下给予较少量的液体和呼吸(呼吸性)支持的效果。沙丁胺醇、肾上腺素和皮质类固醇可清除肺部多余的液体,而利尿剂则是一种促进肺液排出至尿液的药物。 证据更新至2021年7月。 结果 由于可用证据非常有限,我们不能回答我们的综述总览问题。与安慰剂相比,沙丁胺醇可能会减少呼吸急促的持续时间。关于肾上腺素和皮质类固醇的研究没有提供该结局信息。与安慰剂相比,利尿剂的效果证据为非常不确定。关于给予较少量液体的研究没有提供该结局信息。 关于不同类型的呼吸支持在不插管入肺的情况下与给氧相比或两两相比,对呼吸急促持续...

出院计划

3 years 3 months ago
出院计划 本综述的目的是什么? 本综述旨在了解为个体量身定制的出院计划是否提高了所施行的健康照护质量,通过减少延迟出院、减少转回医院及改善患者健康状况。我们还想知道干预成本是多少。我们收集并分析了所有相关的研究来回答这个问题。本文是对原综述的第5次更新。 关键讯息 当人们带着个性化出院计划离院时,住院时间可能略有减少,他们可能有略小的可能性在出院后再入院。未见有多少证据显示,对患者健康状况以及患者对所接受照护满意度的影响。出院计划成本尚不确定。 本综述研究了什么? 出院计划是发展出个性化计划,用于在患者出院前评估其健康和社会照护需求,以支持在医院与家庭或其他条件环境间的及时过渡,并改善出院后服务的组织实施。 本综述的主要结果是什么? 我们发现了33项试验,比较了个性化出院计划与标准出院照护。本综述提示,个性化出院计划可能导致住院时间有非常小的减少,还可能会略微降低因病入院者的再次入院率,而且可能提高患者的满意度。没有多少证据是关于健康状况或出院计划卫生服务成本。 本综述的时效性如何? 综述作者检索了截至2021年4月发表的研究。 作者结论:  为患者个体量身定制的结构化出院计划可能略微缩短患病老年人的初始住院时间和再入院,还可能会略微提高患者对所接受健康照护的满意度。对患者健康状况和医疗资源使用或医疗服务成本的影响,还不确定。 阅读摘要全文…… 研究背景:  ...

减麸或无麸饮食对心血管病的一级预防作用

3 years 3 months ago
减麸或无麸饮食对心血管病的一级预防作用 背景 心血管疾病是心脏和血管的功能紊乱,包括急性冠状动脉和脑血管事件(如心肌梗死和卒中)。约50%由心血管疾病所致的残疾与次佳饮食有关。尤其是,膳食麸质(特定谷物中发现的一种蛋白质)已与广泛的不良健康结局发生关联。例如,不同的胃肠道症状(如吸收不良或腹泻)常发生于那些受麸质相关疾病影响者中,而对此人群唯一有效的治疗常是终身减麸或无麸饮食。低麸和无麸饮食在普通人群中也很受欢迎。然而,一般人群中减麸或无麸饮食的益处和伤害的有关证据却是矛盾的:避免麸质可能与疾病预防有关,但也有人担心,无麸或限麸饮食可能是次佳状态(由于减少了全谷物摄入,而这是饮食的关键组分)。 综述问题 我们综述了可及的研究,以确定低麸或无麸饮食对普通人群心血管疾病的一级预防作用(亦即与健康相关的益处和风险)。 研究特征 证据时效性截止2021年6月。我们找到了1项具有观察性设计的随机对照临床试验(randomised controlled trial, RCT)和3项非随机干预研究(non-randomised studies of interventions, NRSIs)。RCT在意大利进行,纳入了60名健康成年人,随访了6个月。NRSIs纳入了450000多名受试者(美国卫生专业人员或英国普通人群中的成年人(志愿者)),还报告了最长25年以上的随访。在NRSIs中,最低中...

University of Sydney seek Postdoc Research Associate

3 years 3 months ago
  • Full time fixed term until February 2023 (possibility of extension)
  • Great opportunity for an early career researcher to join a supportive and well respected team, making an impact in health based research
  • Base Salary $98,645 + 17% superannuation
  • Applications Close: Sunday 27 February 2022

About the opportunity
The NHMRC Clinical Trials Centre has an exciting opportunity for a Postdoctoral Research Associate to contribute to a range of projects using NextGen evidence synthesis methodologies and conducting meta-research.

Projects will likely include; finding and implementing ideal strategies in childhood obesity prevention interventions with the TOPCHILD collaboration, assessing eating disorder risk in obesity treatment, and conducting meta-research to find and reduce reasons for research waste and increase collaboration and coordination in research.

This is a research-only position, based at the NHMRC Clinical Trials Centre. The successful applicant will be working in the NextGen Evidence Synthesis team within the Evidence Integration Team. There will be an opportunity to develop NextGen evidence synthesis specialist skills, and to attend academic conferences to present project work. The successful applicant will be expected to make an active contribution to papers and new grant submissions arising from this work.

Your key responsibilities will be to:

  • undertake systematic reviews
  • work on individual participant data meta-analyses with large data sets
  • work with a large number of international collaborators and other stakeholders.

About you

  • a strong research background including a PhD qualification and competitive publication track record in a relevant field (systematic reviews, obesity, neonatology, epidemiology, public health, quantitative research or biostatistics)
  • formal qualifications in research methods, such as Masters level qualifications in epidemiology, biostatistics or public health is highly desired
  • ability to work independently, conceive, initiate, organise and manage projects
  • excellent communication and interpersonal skills
  • the successful applicant will combine quantitative research skills with excellent communication and scientific writing skills
  • experience in systematic reviews and meta-analyses is highly desirable
  • experience in research implementation and communication with a broad range of stakeholders (e.g. policy makers, consumers) is desirable, but not essential.

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Sponsorship/work rights for Australia
Please note: Visa sponsorship is not available for this position. For a continuing position, you must be an Australian or New Zealand citizen or an Australian Permanent Resident.

Australian Temporary Residents currently employed at the University of Sydney may be considered for a fixed term contract for the length of their visa, depending on the requirements of the hiring area and the position.

Pre-employment checks
Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement
At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

  • Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted here 
  • If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard.  Click on USYD Find Jobs and apply.
  • For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Lena Germinarios, Recruitment Operations, by email to lena.germinarios@sydney.edu.au
  • The University reserves the right not to proceed with any appointment.
  • Click to view the Position Description for this role.
  • Applications Close Sunday 27 February 2022 11:59 PM
Tuesday, February 22, 2022 Category: Jobs
Lydia Parsonson

卵巢癌初始治疗中,与每3周给药相比,紫杉醇每周给药会改善生存吗?

3 years 3 months ago
卵巢癌初始治疗中,与每3周给药相比,紫杉醇每周给药会改善生存吗? 研究背景 卵巢癌是全球第六大常见癌症。治疗包括联用手术与化疗(最常见包括紫杉醇和卡铂),旨在减少或延缓癌症复发,名为无进展生存期(progression-free survival, PFS),同时改善癌症生存机会,名为总体生存期(overall survival, OS)。有几项临床试验(研究)探究了紫杉醇剂量日程(时间)是否影响这些结局。但是,所报告的研究结果存在矛盾。 综述目的 我们综述了有关不同紫杉醇剂量日程对新诊断卵巢癌女性生存期影响的证据。 研究特征 证据时效性截至2021年11月15日。我们纳入了4项研究,共有3699名受试者。所有纳入研究均为随机对照试验(其受试者被随机分配至2个或多个治疗组之一的临床试验),针对18岁或以上有新诊断卵巢癌的女性。这些研究比较了紫杉醇每周与每3周给药,加用卡铂。 主要发现 我们发现,与紫杉醇每3周给药相比,紫杉醇每周给药并加用卡铂可能会略微改善无进展生存期,尽管总体生存期几乎未见差异(高质量证据)。 对于不良反应,我们发现紫杉醇每周给药加卡铂可能几乎不影响严重中性粒细胞(一种有助于抵抗感染的白细胞)减少(中等质量证据);可能增加严重贫血(红细胞的重要组成部分血红蛋白的水平)(高质量证据),或许几乎不会影响严重神经损伤(低质量证据)。 结论 与卡铂联合用于卵巢癌的初始治...

单独血管成形术或联合支架治疗锁骨下动脉狭窄

3 years 3 months ago
单独血管成形术或联合支架治疗锁骨下动脉狭窄 关键信息 我们在医学文献中找不到任何随机对照临床试验,以比较植入支架(一种像支架一样帮助保持血管畅通的小管)和单独用于治疗锁骨下动脉狭窄(血管变窄或阻塞)的血管成形术(疏通血管的外科手术)的有效性和安全性。目前尚没有足够的证据来确定支架植入术是否比单独的血管成形术更有效。 此问题为何重要? 锁骨下动脉是上胸部、锁骨下方的两条主要血管,来自主动脉弓。左锁骨下动脉为左臂供血,右锁骨下动脉为右臂供血;某些分支为头部和胸部供血。吸烟史、高血压、“良好”(高密度脂蛋白)胆固醇水平较低和外周动脉疾病以及锁骨下动脉狭窄的风险增加有关。锁骨下动脉狭窄常无症状发生。在其发生时,症状包括短暂眩晕(通常被描述为环境旋转),是由于大脑后部血流减少导致,还有手和手臂的血液循环问题。锁骨下动脉狭窄的血管内(微创)治疗包括单独的血管成形术或联合支架植入术。目前尚不清楚,单独的血管成形术或支架植入术是否对锁骨下动脉阻塞者最有益。 我们做了什么? 我们检索了医学文献中关于血管内治疗锁骨下动脉狭窄的随机对照研究,这些研究比较了单独的血管成形术或联合支架植入术。在随机对照研究中,人们接受的治疗或测试是随机决定的。这些通常是提供关乎治疗效果的最可靠证据。 我们发现了什么? 我们未找到任何随机对照研究来帮助回答我们的问题。尚缺乏相关证据,以帮助医疗保健专业人员和锁骨下动脉狭窄患...

Cochrane seeks Cochrane Clinical Answers Editor

3 years 3 months ago

Specifications: Part time (0.5FTE) Permanent/Consultancy contract dependant on location
Salary: £48,500 per annum full time equivalent
Location: Remote, flexible
Application Closing Date:  Friday 4 March 2022

We are looking for a part-time editor to join the Cochrane Clinical Answers (CCA) team.

CCAs provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane Reviews. They are designed to be actionable and to inform point-of-care decision-making and are published in the Cochrane Library (cochranelibrary.com).

Working with the CCA team, the editor will:

  • develop and edit a derivative product that supports the relevance and applicability of Cochrane Reviews, and their presentation and delivery to healthcare professionals;
  • ensure content is developed to best practice, delivered to agreed publishing date, and is consistent with Cochrane’s vision and values;
  • support the CCA Senior Editor with the editorial work and processes of the CCA team (including the CCA Editor in Chief and Cochrane’s publisher), with the aim of improving quality and efficiency through systems and guidance.

Cochrane is a global, independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesizing research findings to produce the best available evidence on what can work, what might harm and where more research is needed. Our work is recognised as the international gold standard for high quality, trusted information.

For this role, an understanding of Cochrane’s work and health research more generally is an advantage, but not essential.

The majority of Cochrane Central Executive staff are based in London, UK, but we will consider candidates from any location.



How to apply

  • For further information on the role and how to apply, please click here.  
  • The deadline to receive your application is by Friday 4 March.  
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
  • Interviews to be held on: tbc
Thursday, February 17, 2022 Category: Jobs
Lydia Parsonson

大规模给药治疗丝虫病的社区观点:质性证据综合

3 years 3 months ago
大规模给药治疗丝虫病的社区观点:质性证据综合 本次综合研究了什么? 大规模给药(mass drug administration, MDA)涉及对整个人群规律给药治疗,不论个体是否患病,亦旨在预防继续传播(自一个人向另一个人传播)。目前推荐在中、低收入国家开展某些疾控项目,包括寄生虫病淋巴丝虫病,此病可致肢体水肿和残疾。对于政府及其卫生服务而言,这是一项需要资金和人力的大型后勤任务,其成功性取决于社区是否服用发放的药物。 本综述中,我们找寻了那些探索人们如何看待和体验这些项目的研究。我们收集了所有相关研究,并纳入29项研究进行综合。 本次综合的目的是什么? 在本次质性研究综合中,我们旨在探讨人们对中、低收入国家MDA项目治疗淋巴丝虫病的看法。 关键信息 人们在决定服药前,必须权衡各种因素。并非每个人都从MDA项目中获益,有些可能会受伤害。因此,坚持服药的决定取决于复杂状况的平衡:对给药政府的信任;他们对疾病的前期了解及其所接收到的项目相关知识;他们经历的伤害;家人、邻居和医务人员的影响;以及他们对给药者的感知与相关体验。 主要的发现是什么? 在我们的分析中,我们纳入了29项研究。纳入的研究广泛涵盖了非洲、东南亚和南美洲的国家,但大多数研究是在印度。这些研究主要探索了在淋巴丝虫病被视为问题的低收入国家中社区成员和给药者的观点与经验。自这些数据中涌现出四个主题。 人们在参与前会权衡利...

压力再分配静态椅有助于预防压疮吗?

3 years 3 months ago
压力再分配静态椅有助于预防压疮吗? 关键信息 尽管是广泛检索,但我们并未找到有任何研究检视压力再分配静态椅是否有助于预防或管理压疮。这是个重要议题,需要有高质量的研究来确定此类椅是否有益于有压疮风险者。 什么是压疮? 压疮是指皮肤及其下组织损伤,可因长时间压力导致。坐姿可以是一个人恢复过程的重要组成部分,但久坐会增加发生压疮的风险。 如何管理压疮? 专门的缓冲垫和表面旨在于人们不得不久坐时对皮肤受压进行再分配。已有更多研究是针对轮椅上所用的压力再分配缓冲垫的作用效果,与标准椅相比。 我们目前尚不知道,相较于标准椅子,压力再分配静态椅子在有风险者之中进行压疮预防或管理是如何有效。 压力再分配静态椅的变化范围,从标准医院椅和住宅环境用椅(无缓冲垫或是手动或有动态功能)到那些整合了压力再分配表面以及在人入座时有升降或倾斜功能的椅子。这些可以按照标准设计或根据个人需求而量身定制设计来生产。 我们想知道什么? 我们想了解,压力再分配静态椅用于预防或管理压疮如何有效,在健康、康复和社会照护环境以及人们可能的度日住处。 我们做了什么? 我们检索了已发表和未发表的研究,用以评估压力再分配静态椅预防或管理压疮。对于语言、发表日期或研究场所,未设限制。 我们发现了什么? 我们未发现任何合格的已完成或注册研究,用以探查压力再分配静态椅预防或管理压疮的效果。 目前尚没有高质量的证据支持或否决压力再分配静...

成人髋关节置换手术

3 years 3 months ago
成人髋关节置换手术 本综述评估了来自随机对照临床试验(randomised controlled trials, RCTs)和类随机对照临床试验(quasi-RCTs)的证据,有关不同类型的髋关节置换用于治疗成人髋部骨折的益处和伤害。 背景 髋部骨折是腿骨顶端出现断裂。这些类型的断裂在老年人中很常见,其骨骼因骨质疏松症而变得脆弱。一种治疗方法是用人工髋关节置换骨折髋部。这可用半髋关节置换术(hemiarthroplasty, HA)来实现,由此取代部分髋关节(关节的球部)。这些替代物可为单极(单个人工关节)或双极(HA内还有一个额外的关节)。亦或者,手术可能替换整个髋关节,这就还包括髋关节球所在的窝——此为全髋关节置换术(total hip arthroplasty, THA)。这两种人工关节都可以在有或没有骨水泥的情况下固定到位。 检索日期 我们检索了RCTs(把受试者随机分至治疗组的临床研究)和类RCTs(此类研究的受试者分组方法不随机,例如按出生日期或医院记录编号),日期截至2020年7月6日。 研究特征 我们纳入了58项研究,涉及10654名成年人,有10662处髋部骨折。研究受试者年龄范围为63到87岁,71%为女性,这在此类髋部骨折患者中常见。 主要结果 骨水泥HAs相较于非骨水泥HAs(17项研究,3644名受试者) 我们发现,骨水泥HAs可改善健康相关生活质量(h...

预防乳牙龋齿的封闭剂

3 years 3 months ago
预防乳牙龋齿的封闭剂 系统综述问题 将封闭剂涂在口腔后部乳牙的咬合面上可以防止蛀牙形成吗? 研究背景 蛀牙是儿童时期最常见的疾病之一,会影响儿童的整体健康。最常受影响的牙齿是后牙,其咬合面不平整,并且有窝沟(凹坑和裂缝),可以保留食物残渣和细菌,导致蛀牙(龋洞)的形成。此外,这些窝沟的开口太小,牙刷刷毛无法完全进入,难以清洁。封闭窝沟是预防后牙龋坏的方法之一。封闭剂可作为对抗食物和细菌的保护屏障,从而防止它们对牙齿表面的伤害。 研究特征 我们纳入了九项研究,共包含1120名年龄在18个月至8岁之间的儿童。这些研究使用了多种牙齿封闭剂来预防乳牙蛀牙。我们评估的大多数研究总体上存在高偏倚风险,因为测量结局的牙科专业人员可以看到是否放置了封闭剂,也可以区分封闭剂材料。 主要结果 三项研究比较了封闭剂与不使用封闭剂的情况,六项研究比较了不同的材料或工艺来封闭牙齿表面。由于研究设计在封闭剂类型、试验开始时儿童的年龄和随访时间方面存在重要差异,因此我们无法合并数据。只有一项试验评估并报告了副作用,其性质是放置封闭剂材料时出现呕吐反射。 证据质量 我们发现了关于封闭剂在预防儿童后乳牙咬合面蛀牙方面有效性的低质量证据。因此,我们无法得出与不使用封闭剂或不同封闭剂相比,封闭剂在预防儿童乳牙蛀牙方面的有效性的结论。需要开展更多具有较长随访时间的良好研究。 证据的时效性如何? 本综述纳入截至2021年...

Cochrane EPOC seek Systematic Reviewer

3 years 3 months ago

Location: Oxford
Salary: £33,309 to £40,927
Hours: Part Time
Contract Type: Fixed-Term/Contract
Closes: 11th March 2022
Job Ref: 155759

Oxford Population Health (The Nuffield Department of Population Health) contains world-renowned population health research groups and provides an excellent environment for multi-disciplinary research and teaching. The Clinical Trial Service Unit is a major international research institute within Oxford Population Health, and is one of the world’s leading centres for research into chronic diseases, such as cancer and heart disease.

As a Systematic Reviewer you will work with the Cochrane Effective Practice and Organisation of Care (EPOC) group in a multidisciplinary research environment. You will provide systematic review expertise to authors of ongoing EPOC systematic reviews, and take a lead or collaborate with existing authors on completing and publishing high priority EPOC reviews.

To be considered you will have a PhD in a health related subject (or equivalent experience), an understanding of statistics and experience of conducting and publishing systematic reviews. You will also have strong quantitative skills the ability to communication clearly with others.

  • Apply for the role here
  • The post is part-time (between 60-80%FTE) and fixed term to 31st March 2023.
  • The closing date for completed applications is 12.00 noon on 11th March 2022.   
  • Contact Email :recruit@ndph.ox.ac.uk
Thursday, February 10, 2022 Category: Jobs
Lydia Parsonson

Cochrane Connects Event, 1 March – Register Now

3 years 3 months ago

Register for Cochrane Connects meeting on research waste, including Cochrane-REWARD prize ceremony, and research integrity

Cochrane Connects - 1 March 17:00 – 18:00 GMT (check in your time zone)Register Now

Join us for the next Cochrane Connects meeting, which will focus on research waste and research integrity.

This special edition of Cochrane Connects will feature the Cochrane-REWARD prize ceremony. Since 2017, the prize has gathered, assessed and publicized local or pilot initiatives with the potential to reduce research waste if scaled up globally. We will be joined by representatives of the external prize committee, who will announce the winners of the first and second prizes live. The winners will share more about their initiatives in short presentations and answer audience questions.



There will also be an update on Cochrane’s research integrity activities from Senior Research Integrity Editor Prof Lisa Bero, followed by an opportunity for interactive discussion on what more Cochrane could do in this area, and on research waste in the future.

Cochrane Connects is a series of free online events open to everyone. You will have the opportunity to meet colleagues and peers, hear about and celebrate achievements from the community and take part in active discussions to help shape Cochrane for the future.

Register now by following the link here.

Monday, February 14, 2022
Lydia Parsonson

药物预防创伤后应激障碍(PTSD)

3 years 3 months ago
药物预防创伤后应激障碍(PTSD) 本综述为何重要? 创伤后应激障碍(post-traumatic stress disorder, PTSD)是严重的致残状况,可能发生于创伤事件暴露者中。此类事件可对那些事件经历者的生活及被爱者的生活产生持久的负面反响。 研究已显示,PTSD患者的大脑如何工作会有些改变。有些研究者据此提出,作为预防PTSD的方法,创伤事件后要赶快用上针对这些改变的药物。然而,大多数创伤事件经历者并不会发生PTSD。因此,创伤事件后很快给予药物治疗需要谨慎评价其有效性,包括平衡副作用和PTSD发生风险。 谁会感兴趣? -暴露于创伤事件者及其家人、朋友和被爱者 -心理健康专业工作人员 -创伤和急诊医学专业工作人员 -创伤受害者和武装部队退伍军人的照顾者 本综述要回答何问题? 对创伤事件暴露者(有或无心理症状),某些药物是否比其他药物或安慰剂(假药丸)对以下方面更有效: -减轻PTSD症狀严重性? -减少因副作用而停药的人数? -降低PTSD发生可能性? 纳入了哪些研究? 我们检索了科学数据库中的研究,其中受试者被随机分配接受一种药物治疗,旨在预防PTSD及其症状或减轻其严重性。我们纳入的研究发表截至2020年11月。我们所选的研究,涉及经历任何类型创伤事件的成人并为其提供了治疗,不论受试者有无心理症状。 我们纳入了13项研究,共2023名受试者。其中有1项研究贡献...

Millions of lives could be saved if health evidence and communication is put at forefront of pandemic preparedness

3 years 3 months ago

New Cochrane Convenes report recommends urgent action among those who fund, generate and use evidence to ensure the world is better prepared.

Two years in, it is clear that COVID-19 has created an unprecedented focus on health evidence for people working in governments, businesses and non-governmental organizations as well as members of the public. Responsible governments and other bodies have “followed the science” or claimed to.

Since the early days of the pandemic, Cochrane and other research synthesis organizations have been curating and analysing the thousands of studies being published on COVID-19 to help decision makers make sense of the evidence. The arrival of Omicron reinforced the need for timely evidence as decision makers across the globe scrambled to guide healthcare services and the public once again.

Dr Karla Soares-Weiser, Editor in Chief, Cochrane explains, “Like many others, I have been deeply concerned about the widening of existing inequities and the way that those already vulnerable have been disproportionately affected by the pandemic. As a community of evidence producers and users, we were not as prepared to respond to the COVID-19 pandemic as we could have been.”

Seeking to learn from the experience, in October 2021, Cochrane, invited key thought leaders from around the world to reflect on their experiences of producing, sharing and using evidence during the pandemic. Working with co-sponsor WHO, and co-organizer COVID-END, the event was convened with a view to making a call to action on areas for improvement. A resulting report, published today, discusses the challenges faced and presents recommendations from the meeting.

The report highlights three major challenges:

  • The evidence response to the COVID-19 pandemic has been inequitable –in terms of the focus of the evidence, who has been producing it and who it reaches
  • Current scientific methods, tools and processes have been pushed to their limits in trying to answer questions at the speed demanded
  • In the face of an infodemic, researchers have struggled to communicate scientific uncertainties and gain trust in the evidence 

Over the course of 2022, Cochrane will engage with a wider group of experts to take forward the most pressing recommendations, including:

  • Building support for creation of evidence synthesis unit/s in low and middle-income countries to help address global imbalance. This will mean some of the world’s poorest communities will have access to relevant evidence on what works in their region.
  • Investing in science communications which will strengthen our ability to communicate uncertainty in a way citizens understand, as well as being more proactive about science communication. 
  • Strengthening of tools, methods, processes and relationships to ensure a rapid and relevant evidence response at national and global levels for the next global health emergency. 

The report also calls on other key stakeholders in evidence generation and use to take urgent action:

  • Funders to provide resources to meet national and international research needs, which must address inequities; and particularly to fund evidence generation, communication, networks and infrastructure in low- and middle-income countries
  • Politicians to demand evidence; be transparent about how (and what) evidence is used in decision making; and to hold to account those deliberately creating and sharing mis/disinformation 
  • Researchers to support research transparency and data sharing; and raise the alarm about fraudulent studies
  • Science communicators to learn what works in communicating uncertainty, generating trust in evidence and countering mis/disinformation

Dr John Grove, Director of the Quality assurance, norms and standards department, Science division. WHO HQ, said,

“WHO, with our clear global mandate, will continue to bring focus to the priority questions, design what is most relevant for countries, combat misinformation, push for reducing inequities of access to the best science, and redouble activities to lead and coordinate these aspects of the response. Our main platform will continue to be building out a living approach to guidance development and implementation.”

 
Dr Karla Soares-Weiser, Editor in Chief, Cochrane said,

"We have all seen how the COVID-19 pandemic and its wider impacts have claimed many lives around the world. Cochrane Convenes was organized out of a sense of responsibility to learn from our experiences of the evidence response so that we can be better equipped for future health emergencies. 

The Cochrane community is a powerful and diverse global network, which we can harness to drive change. Of course, we cannot, and will not, do this in isolation. I hope that this report is therefore a call to action to funders, political leaders and other parts of the research community to join us in taking the recommendations forward."

Wednesday, February 16, 2022
Muriah Umoquit

Cochrane seeks Evidence Synthesis Methodology Editor

3 years 3 months ago

Specifications: Permanent
Salary: circa £40,000 per annum
Location: UK
Application Closing Date:  Friday 25 February 2022

Cochrane’s Methods Support Unit was established in 2019 to provide methodological support in the production of high quality, high priority Cochrane systematic reviews.

The Methods Support Unit provides guidance and hands on statistical and methods support to Cochrane systematic reviews, including those using complex methods or non-randomised study designs. The unit comprises two part time Statistical Editors and one full time Evidence Synthesis Methodology Editor.  

As Evidence Synthesis Methodology Editor, you will provide methodological support and general systematic review methods advice for reviews in process, field queries from the Community Support Team, and provide methods peer review as requested. You may also be required to provide subject matter expertise for the development of specific features in tools and software used in the production of Cochrane Reviews.

The role will require a very good understanding of methods such as the assessment of risk of bias for different study designs, application of GRADE and interpretation of findings in the review. An understanding of statistical meta-analysis methods is advantageous in the role, although specialist statistical editors in the unit will be able to provide this advice.

The majority of Cochrane Central Executive staff are located in London, UK, however flexible location or a part-time appointment are possible for the right candidate.

How to apply

  • For further information on the role and how to apply, please click here.  
  • The deadline to receive your application is by Friday 25 February.  
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
Wednesday, February 9, 2022 Category: Jobs
Lydia Parsonson

Trusted information needs to be protected on social media as much as misinformation needs to be challenged

3 years 4 months ago

Recent removal of Cochrane’s Instagram post and shadowban highlight the realities of Cochrane’s call against misinformation

Cochrane’s health evidence syntheses are recognised as the international gold standard for high quality, trusted information. Our reviews are used to support global and national health guidelines and policy. We advocate for evidence-informed healthcare and make our trusted evidence accessible and available to all. One way we do this is using social media to reach different audiences. 

In recent days, Cochrane has again been the subject of an Instagram misinformation blunder, with a post about a Cochrane Review on Ivermectin for prevention and treatment of COVID-19 being removed from the platform. Also Cochrane’s Instagram account has been denied the verification blue check mark several times. We are aware that other research publishers, such as the BMJ, have also experienced similar issues.

The first time this happened in November, Cochrane’s Instagram account was ‘shadowbanned’ for a few weeks; people could not tag or mention @cochraneorg on the platform. While little specifics were given, there was a notification that the account ‘repeatedly posted content that goes against Community Guidelines on false content about COVID-19 or vaccines.’ This shadowban happened just days after Cochrane helped lead a campaign to tackle misinformation for World Evidence-Based Healthcare Day and launched a course with Lifeology about identifying and preventing infodemics.

“The removal of our Cochrane post on Instagram comes just days before the launch of the Cochrane Convenes Report which calls for generating trust in evidence and countering mis/disinformation.” says Cochrane’s Editor in Chief, Dr Karla Soares-Weiser.

Drawing on experiences of the COVID-19 pandemic, Cochrane Convenes brought together leaders in health research and health evidence to explore and recommend the changes needed in evidence synthesis to prepare for and respond to future global health emergencies. The full report of the recommendations is being released 16 February.

“It’s not clear if there is an issue with Instagram’s algorithm or if the issue lies with people ‘gaming’ policies and reporting posts as misinformation when they are not. What is clear is that there is an issue with how you hold those deliberately creating and sharing mis/disinformation to account and how you form accreditation and approval for official sources of evidence that have met certain quality control standards. We need to make it easier for people to access trustworthy information – and that includes on social media.”

Cochrane is a proud supporter of WHO’s call to action on infodemic management and is currently collaborating with science communicators at Lifeology and the Association for Healthcare Social Media  and welcomes the opportunity to work directly with social media platforms and with others interested in tackling misinformation.

 

Tuesday, February 8, 2022
Muriah Umoquit